Hepatology Knowledge into Practice Podcast

About Hepatology Knowledge into Practice Podcast

A summary of new trial data, guideline recommendations and expert opinion across hepatology care, run by Hepatology Knowledge into Practice (https://hepatology.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.

Publisher

Hepatology Knowledge Into Practice

Category

health & fitness

Language

en

Explicit

No

First episode

19 Apr 2022

Latest episode

7 Jun 2022

Latest episodes

4 episodes in the feed.

1. 

   7 Jun 2022

   NASH: Current and future therapies | With Prof. Philip Newsome

   NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future. Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: References are available here (https://hepatology.knowledgeintopractice.com/learning/podcast/nash-current-and-future-therapies/pre-assessment) Disclosures: Prof. Philip Newsome declares the following: Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

2. 

   25 May 2022

   NASH: Advances in non-invasive screening | With Dr Kenneth Cusi

   NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developing NAFLD, how can we identify those with NASH? In this podcast episode, we are joined by Dr Kenneth Cusi to discuss how patients can be risk stratified using non-invasive biomarkers and imaging techniques. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com (https://hepatology.knowledgeintopractice.com/), where you can find all past episodes of the podcast as well as other free CME resources. References: Nones RB et al. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist? Arch Endocrinol Metab. 2017 May-Jun;61(3):276-281. (https://pubmed.ncbi.nlm.nih.gov/28225987/) Shah AG et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. (https://linkinghub.elsevier.com/retrieve/pii/S1542-3565(09)00533-3) Newsome PN et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. (https://linkinghub.elsevier.com/retrieve/pii/S2468-1253(19)30383-8) European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts 2016;9(2):65-90. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644799/) Disclosures: Dr Kenneth Cusi disclosures are as follows: Research Support - Poxel, Zydus, Echosens, Inventiva, Novo Nordisk Consultant - Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

3. 

   19 Apr 2022

   NASH: What’s behind the link with T2D and obesity? | With Prof. Giulio Marchesini

   People with type 2 diabetes or obesity are at higher risk of developing non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). Some estimates report a prevalence of NAFLD of 60% in people with type 2 diabetes, rising to 78% in those who also have obesity. So what’s behind this link? In this podcast episode, Professor Giulio Marchesini explores the relationships between NAFLD, type 2 diabetes and obesity and offers advice for healthcare professionals caring for people with one or more of these conditions. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com (//hepatology.knowledgeintopractice.com), where you can find all past episodes of the podcast as well as other free CME resources. References: Dai W, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8179. (https://pubmed.ncbi.nlm.nih.gov/28953675/) Padda J, et al. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus. 2021 Aug 20;13(8):e17321. (https://pubmed.ncbi.nlm.nih.gov/34557367/) Mantovani A, et al. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018 Feb; 41(2):372-382. (https://diabetesjournals.org/care/article/41/2/372/30381/Nonalcoholic-Fatty-Liver-Disease-and-Risk-of) Targher G, et al. Diabetologia. 2008 Mar; 51(3):444-50. (https://pubmed.ncbi.nlm.nih.gov/18058083/) Godoy-Matos AF, et al. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020 Jul 14;12:60. (https://pubmed.ncbi.nlm.nih.gov/32684985/) Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1. (https://pubmed.ncbi.nlm.nih.gov/32044314/) Kim D, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan;14(1):132-8.e4. (https://pubmed.ncbi.nlm.nih.gov/26226099/) Disclosures: Prof. Giulio Marchesini declares the following: Advisory Board: Novartis, Eli Lilly, Gilead, MSD, Pfzier, Astra-Zeneca Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

4. 

   19 Apr 2022

   NASH: Pathogenesis and pathophysiology | With Prof. Zobair Younossi

   Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease, of which an advanced form is non-alcoholic steatohepatitis (NASH). But how does this condition develop, and why is it associated with poor outcomes? In this podcast episode, Professor Zobair Younossi discusses the latest evidence on the pathogenesis and pathophysiology of NASH, and how it can lead to poor outcomes. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com (//hepatology.knowledgeintopractice.com), where you can see all episodes of the podcast as well as other free CME resources. References: Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1. Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020 Jan 1;41(1):bnz009. Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care. 2018 Feb;41(2):341-347. Disclosures: Professor Zobair Younossi declares the following: Consultant: Merck, Gilead, Siemens, Intercept, Bristol Myers Squibb Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Contact Hepatology Knowledge into Practice Podcast

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.